DAPA-HF is the first outcomes
trial with an SGLT2 inhibitor,
Farxiga for treatment
for patients with HFrEF
HOPE for people living with heart failure has been presented on the 1st September 2019 BST 1.30pm at ESC Congress in Paris 2019. Detailed results of the Phase III DAPA-HF trial show all the primary endpoints achieved with Farxiga, an SGLT2 inhibitor for treatment for patients with HFrEF (Heart failure with reduced ejection fraction)
“This is so important for people living with heart failure that another drug therapy has been added to the armoury of tackling heart failure. It is even more so important that the trial achieved the primary endpoints for those without Type II diabetes as well. This is a significant step forward in the weaponisation of therapies against heart failure which impacts 1 million people across the UK, 15 million across Europe and 30 million + across the Globe” says Nick Hartshorne-Evans
As a leading patient stakeholder in the heart failure conversation, the Pumping Marvellous Foundation are very excited with the results of the DAPA-HF trial and how this may help people improve their quality of life and increase their expectations of managing their heart failure well.
We must also congratulate Dr John McMurray from the University of Glasgow and the trial team for a superbly run and efficient trial. We hope that the trial results lead to more therapy options for patients living with heart failure.
Link to Astrazeneca’s website and official press release here